NCT02816710

Conbercept Injection in Treatment of Severe Proliferative Diabetic Retinopathy

Different Conbercept Injection Methods in Treatment of Severe Proliferative Diabetic Retinopathy

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 112 (actual)
• Sponsor: Ruijin Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate efficacy of different intravitreal Conbercept injection therapy in the treatment of severe proliferative diabetic retinopathy.

Detailed description

To assess the clinical effects of preoperative, intraoperative or preoperative combined with intraoperative intravitreal conbercept (IVC) injection in pars plana vitrectomy (PPV) with silicone oil tamponade for severe proliferative diabetic retinopathy (PDR). Methods. These patients were randomly assigned to three groups: Group 1 received an IVC injection 3 to 5 days before surgery; Group 2 received an IVC injection at the end of surgery; and Group 3 received an IVC injection 3 to 5 days before PPV as well as an IVC injection at the end of PPV. Follow-up examinations were performed for at least six months after surgery.

Conditions

• Proliferative Diabetic Retinopathy
• Tractional Retinal Detachment

Interventions

Type	Name	Description
DRUG	Conbercept	Conbercept is a humanized soluble fusion protein which has a high binding affinity to the Fc region of human immunoglobulin G1 simultaneously. Prior clinical studies have demonstrated that intravitreal conbercept (IVC) inhibits the process of angiogenesis in vivo and in vitro, and has been recognized as a novel effective treatment strategy for neovascularization, providing an alternative treatment option for ophthalmologists.

Timeline

• Start date: 2016-07-01
• Primary completion: 2017-09-01
• Completion: 2017-09-01
• First posted: 2016-06-28
• Last updated: 2019-11-21
• Results posted: 2019-11-21

Locations

1 site across 1 country: China